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Abstract 
 
Monoclonal antibodies (mAb) have revolutionised the way in which we treat disease. 
From cancer to autoimmunity, antibody therapy has been responsible for some of 
the most impressive clinical responses observed in the last 2 decades.  A key 
component of this success has been their generally low levels of toxicity, and unique 
mechanisms of action. These two facets have allowed them to a) be integrated 
rapidly into clinical practice in combination with conventional radio- and chemo-
therapies and b) to avoid the resistance mechanisms typically observed with 
classical small molecule drugs, such as upregulation of drug efflux transporters, 
dysregulation of apoptosis and mutations in key target enzymes/pathways.  
 
Although success with mAb therapies has been impressive, they are also subject to 
their own resistance mechanisms. In this perspective we discuss the various ways in 
which mAb therapeutics can be inhibited, concentrating mainly on the ways in which 
they can be removed from the target cell surface - a process called modulation. This 
can be achieved either in a cis-fashion on a single cell or in trans, precipitated by 
engagement with a second phagocytic cell. The evidence for each of these 
processes will be discussed, in addition to possible therapeutic strategies that might 
be employed to inhibit or reverse them. 
Abbreviations: Fc gamma receptor, FcR; monoclonal antibody, mAb 
 
Key Words: Antibodies, Fc gamma receptor, FcγRIIB, Modulation, Shaving, 
Immunotherapy, CD20, Tumour Resistance 
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Introduction 
 
The large scale use of antibodies as potential therapeutics first became a reality in 
1975 when Kohler and Milstein described how to generate monoclonal antibodies 
(mAb) [1]. This technical advancement, for which the inventors were awarded the 
Nobel prize for medicine in 1984, allowed an infinite supply of a single mAb 
specificity to be produced for the first time, thereby facilitating the careful 
development and controlled production required for translation into human 
therapeutics.  The intervening decades have not been without challenges: the issue 
of immunogenicity of the original murine antibodies, and the unexpected toxicity of 
some antibody specificities have represented significant setbacks in the field but 
these have now largely been overcome through antibody engineering (chimerisation, 
humanisation, phage display), the development of mice expressing human antibody 
genes and more rigorous pre-clinical testing and careful trial management (reviewed 
in [2] and [3]).  
In particular, several mAb have clearly demonstrated the potential benefits of mAb 
therapeutics. The anti-CD20 mAb rituximab was the first to be approved for use in 
oncology and heralded in a new era in the treatment of B cell malignancies [4], 
improving response rates and overall survival in combination with chemotherapy and 
significantly raising the bar for new therapies. It has more recently also made 
significant inroads into autoimmune disorders, revealing perhaps surprising efficacy 
in diseases not previously associated with B cell dysfunction [5]. Its success has 
been to the extent that frequently clinical data is now assessed as being from either 
the pre- or post-rituximab era. In autoimmunity, the anti-tumour necrosis factor (TNF) 
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α mAb infliximab has had a similar impact. Approved first for Crohn's disease in 
1998, it has since been approved for ankylosing spondylitis, psoriatic arthritis, 
rheumatoid arthritis [6], and ulcerative colitis. Like rituximab, it has gone on to be 
administered to millions of patients. However, as well as illustrating the success of 
mAb therapeutics these two reagents also illustrate a new phenomenon – that of 
antibody resistance.  
 
As detailed above, mAb function very differently to conventional small molecule 
therapeutics. They work through a variety of potential effector mechanisms 
(reviewed previously [7]). In essence, they bind to their specific target molecule and 
in doing so may block the interaction with the natural ligand (as in the case of 
infliximab – it binds TNF - preventing it from binding to its receptor), modulate target 
molecule signalling (as in the case of Herceptin by preventing Her-2neu 
dimerization), and/or engage the effector systems of the immune system. These 
latter may be serum proteins such as complement or cellular effectors such as NK 
cells and macrophages which are engaged through key receptors on the cell surface 
known as Fc receptors which bind the Fc region of the antibody. 
 
As discussed elsewhere and in keeping with the fact that most therapeutic mAb are 
of the IgG class, Fc receptors and particularly Fc gamma receptors (FcγR), are 
pivotal for the activity of the majority of therapeutic mAb. FcγR represent a family of 
evolutionary related receptors which in mammals may be broadly subdivided with 
regards to their affinity for IgG and downstream signalling effects (reviewed in  [8]). 
Humans and mice have a single, high affinity FcγR, capable of binding monomeric 
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IgG, with the remainder all low-medium affinity, only binding multimeric IgG in the 
form of soluble or cell-bound immune complexes. The majority of FcγR are activatory 
receptors and have a positive signalling function, engendered through their 
association with the common FcR gamma chain, which contains an immunoreceptor 
tyrosine-based activation motif (ITAM). However, in both mouse and man there is a 
single inhibitory FcγR, FcγRIIB (CD32B) which has an immunoreceptor tyrosine-
based inhibitory motif (ITIM) and serves to reduce intracellular signalling arising from 
activatory FcγR and other stimulatory receptors via the recruitment of SHIP [9].  
 
Using anti-CD20 mAb as a model, we and others have tried to identify the key roles 
that FcγR play in mAb effector function [7]  and how resistance might be elicited 
[10,11] (Figure 1). Based on in vitro functional differences CD20 mAb can be 
classified as type I (rituximab-like) or type II (tositumomab-like) [7]. Type I display a 
potent ability to activate complement through enhanced recruitment of C1q [12] due 
to the efficient clustering of antibody Fc regions [13]; an activity directly linked to their 
ability to redistribute CD20 to lipid raft microdomains of the plasma membrane. In 
contrast, type II anti-CD20 mAb do not display either of these properties but instead 
evoke strong homotypic adhesion [14] and a non-apoptotic form of lysosomal cell 
death [14-17]. In addition, we observed that type I anti-CD20 mAb undergo more 
rapid internalization from the cell surface, in contrast to type II mAb [18-20]. Below 
we discuss the various ways in which the study of these two different types of mAb 
have elucidated a number of mechanisms of mAb resistance, before discussing how 
they may be overcome. 
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Antigenic modulation: Antibody internalisation 
Historically, CD20 was considered to be an ideal target for mAb therapy due to its 
high expression on malignant cells, its B cell lineage restriction, absence from 
antibody-producing plasma cells and stem cells, and apparent lack of antigenic 
modulation [21,22]. Whilst the first three properties hold true, it is now appreciated 
that antigenic modulation of CD20 occurs in some circumstances.  
Using transgenic mice expressing human CD20 on the surface of the B cell 
population, we demonstrated that type II anti-CD20 mAb consistently outperformed 
type I mAb in mediating B cell depletion in vivo [23]. Both the extent and duration of 
depletion was greater in animals treated with the type II mAb and was independent 
of differential complement activation [23] and programmed cell death [18] mediated 
by type I and II mAb.  Instead, type I anti-CD20 mAb were internalised and degraded 
in transgenic mouse B cells in vivo as well as primary and malignant human B cells 
treated in vitro, in contrast to the type II mAb [18]. Internalisation was associated with 
a reduction in both antibody half-life [23] and phagocytosis of opsonised cells [24] by 
effectors (Figure 1), suggesting that internalisation of type I anti-CD20 mAb-ligated 
CD20 leads to reduced therapeutic efficacy and increased consumption of mAb from 
the serum. 
 
Mechanisms of internalisation 
The mechanism of internalisation of type I anti-CD20 mAb was investigated by Lim 
et al. who demonstrated that the rate was slower in response to ligation by a F(ab’)2 
fragment of rituximab, suggesting a potential role for Fc receptor engagement [19]. 
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Internalisation occurred in purified B cells which express only the inhibitory FcγRIIB 
and engaging FcγRIIB with a specific blocking mAb inhibited the process. 
Furthermore, there was a negative correlation between the cell surface expression of 
FcγRIIB and the proportion of rituximab remaining on the cell surface after in vitro 
culture [19]. We also demonstrated that the ITIM of FcγRIIB was phosphorylated in 
response to rituximab, indicating that a direct interaction between the Fc domain of 
the mAb and the Fc-binding domain of the FcγR augmented internalisation. 
 
Type I anti-CD20 mAb and FcγRIIB may interact in either of two ways; engaging 
adjacent cells in trans, or on the surface of a single cell in cis. By repeating our 
experiments under conditions in which direct cell-cell interaction was unlikely, Lim et 
al. demonstrated that a cis interaction between type I anti-CD20 mAb and FcγRIIB 
was required to augment internalisation [19], a process termed antibody bipolar 
bridging. Finally, we demonstrated reduced survival after rituximab treatment in 
patients with mantle cell lymphoma whose tumours expressed high levels of 
FcγRIIB, after treatment with rituximab-containing immunochemotherapy [19], 
compared to those expressing low levels. This same observation was also made 
later in patients with follicular lymphoma treated with rituximab monotherapy [25], 
supporting the assertion that internalisation may reduce the therapeutic efficacy of 
type I anti-CD20 mAb therapy when used clinically. 
 
Interaction between type I anti-CD20 mAb:CD20 and FcγRIIB expressed in cis is 
analogous to the interaction between FcγRIIB and immune complexes formed by 
antibody-coated antigen. Upon antibody bound-antigen binding to its cognate B cell 
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receptor (BCR), the immune complex binds to FcγRIIB in cis via the Fc domain of 
the bound antibody, bringing the inhibitory FcγR and the BCR into close proximity in 
the plasma membrane; an interaction that inhibits BCR activation and is believed to 
act as a negative feedback loop for antigen-specific B cell responses [26].  In 
addition to inhibiting BCR activation, binding of immune complex in the form of heat 
aggregated IgG has been shown to induce rapid internalisation of the B2 isoform of 
FcγRIIB that is dependent on the presence of a complete ITIM sequence in the 
cytoplasmic domain [27,28]. These data suggested that the interaction between type 
I anti-CD20 mAb and FcγRIIB may bring FcγRIIB and CD20 into close proximity in 
the plasma membrane, augmenting internalisation of the trimeric complex via 
phosphorylation of the FcγRIIB ITIM, analogous to the response with immune 
complex. However, investigations by Vaughan et al. demonstrated that a truncated 
mutant form of FcγRIIB lacking the entire cytoplasmic domain was able to augment 
internalisation of type I anti-CD20 mAb-ligated CD20 as effectively as the wild type 
receptor [29]. This suggested that unlike the interaction between FcγRIIB and 
immune complex, internalisation of antibody-ligated CD20 was not mediated via 
FcγR-dependent signal transduction, implying that the role of FcγRIIB was restricted 
to physical/structural interactions. 
 
Role of lipid rafts 
Interestingly, type I anti-CD20 mAb are not unique in their ability to interact with 
FcγRIIB. In fact, many mAb targeting antigens on B cells interact with FcγRIIB in cis 
in direct proportion to the amount of mAb bound to the cell surface, including mAb to 
MHC II, CD40 and CD38 [20]. However, in the majority of cases these interactions 
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fail to alter the rate of internalisation of the mAb-ligated receptor, with only anti-CD38 
and anti-CD19 mAb significantly affected [20]. 
 
In an attempt to further elucidate the mechanism of antigenic modulation, we have 
investigated the role that lipid rafts may play in FcγRIIB-augmented internalisation of 
mAb-ligated CD20. Type I anti-CD20 mAb mediate redistribution of CD20 to lipid 
rafts [30,31] in contrast to type II anti-CD20 mAb [12] and many other mAb directed 
to B cell surface receptors. Furthermore, FcγRIIB also redistributes to lipid rafts upon 
crosslinking with the BCR [32-34]. Redistribution to lipid rafts and subsequent 
endocytosis is a well-recognised pathway of internalisation for many receptor:ligand 
complexes and viruses [35]. We speculated that the interaction between FcγRIIB 
and rituximab in lipid rafts may be required for augmenting internalisation [29], 
explaining why the rate of internalisation of type II anti-CD20 mAb and mAb directed 
to other receptors remain largely unchanged, despite phosphorylation of FcγRIIB. 
To investigate the role of lipid rafts, we transfected human myeloma cells with 
mutant versions of CD20 unable to redistribute to lipid rafts [14,31]. In the absence of 
FcγRIIB, cells expressing these mutant forms of CD20 demonstrated slower 
internalisation of type I anti-CD20 mAb than cells expressing wild type CD20 
suggesting that redistribution of CD20 to rafts is important for internalisation 
(unpublished observations).  However, internalisation was augmented when cells 
were co-transfected with FcγRIIB, suggesting that FcγRIIB was able to compensate 
for the mutation by acting to chaperone mutant CD20 into lipid rafts. To investigate 
this possibility we prepared a transmembrane mutant form of FcγRIIB based on a 
similar mutation made in the transmembrane domain of FcγRIIA [36] that is unable to 
redistribute to rafts. This mutant form of FcγRIIB also augmented internalisation of 
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CD20, suggesting that its role in the process may be independent of its ability to 
enter lipid rafts (unpublished observations). 
It is still unclear how the interaction between FcγRIIB and type I anti-CD20 mAb 
augments internalisation of CD20. A prerequisite for endocytosis is the formation of 
membrane curvature that allows the budding of endocytic vesicles. Recently, 
Stachowiak et al. demonstrated that steric confinement of highly crowded protein 
within regions of artificial lipid membranes is enough to drive membrane puckering 
and lipid tubule formation in the membrane [37], observing that puckering increases 
with protein concentration. We have observed punctate staining of CD20 that co-
localises with FcγRIIB upon ligation with type I anti-CD20 mAb, in contrast to diffuse 
staining observed with the non-redistributing type II mAb [18-20,29]. The high density 
redistribution of CD20 and FcγRIIB induced by type I anti-CD20 mAb-ligation 
resembles the high density staining observed in the artificial membranes generated 
by Stachowiak et al. [37] and may therefore be sufficient to trigger membrane 
puckering and subsequent endocytosis. The function of FcγRIIB in this process may 
be to form high affinity interactions with the mAb-ligated receptor, promoting high 
density clustering within the membrane, necessary for membrane distortion. This 
does not fully explain why type II anti-CD20 mAb do not augment internalisation of 
CD20, which also interact with FcγRIIB expressed in cis. However, the crystal 
structure of the type II mAb GA101 (obinituzumab) indicates that type II antibodies 
bind CD20 in a different orientation to type I anti-CD20 mAb [38]. This difference 
may alter the affinity or density with which type I and II mAb interact with FcγR in cis. 
Although type II mAb interact with and phosphorylate FcγRIIB, the level of activation 
is much less [20].  The altered elbow angle of type II anti-CD20 mAb may not be 
sufficient to drive the clustering required to elicit membrane puckering and 
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subsequent endocytosis. This, coupled with the inability of type II mAb to induce 
redistribution of CD20 to lipid raft domains may result in type II mAb and mAb 
directed to other protein targets, remaining on the cell surface. 
 
Antigenic modulation: Antibody shaving 
An alternative explanation for the phenomenon of antibody resistance is antibody 
shaving or trogocytosis. The shaving reaction was first implicated in resistance to 
mAb treatment in studies with rituximab in CLL patients by the group of Ron Taylor 
[39]. They proposed this mechanism to help explain the clinical observation that after 
initial infusions of rituximab, circulating CLL cells were reduced in number and then 
replaced by CD20 low/negative CLL cells which persisted in the face of ongoing mAb 
administrations [40].  
 
In the shaving reaction antibody and antigen complexes are nibbled or plucked 
(shaved) from the target cell surface in an FcγR-dependent reaction by monocytes or 
macrophages [39]. Although originally postulated to be mediated by FcγRI, shaving 
has since been demonstrated to be possible with any, and all, FcγR and seems 
simply to require productive contact between antigen-antibody complexes and FcγR 
expressing effector cells. Indeed in one mouse model system the inhibitory FcγRIIB 
was also demonstrated to mediate shaving [41]. It is noteworthy that these data 
regarding FcγR usage were obtained using an intraperitoneal tumour mouse model 
where previously complement had been demonstrated to play a role [42]. It is 
therefore possible that complement receptors which are expressed on monocytes 
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and macrophages, and themselves able to mediate phagocytosis [43,44] may have 
been active in this system making delineation of the role of FcγR difficult. 
Taylor and colleagues proposed that the shaving process occurred when effector cell 
populations become saturated and exhausted (reviewed in [45]). Shaving is 
proposed to leave the cells viable but refractory to clearance by subsequent effector 
functions as they are no longer coated with mAb.  Although the depletion of 
complement components [40] and activation of NK cells [46] has been demonstrated 
after rituximab administration no formal demonstration of reduction in capacity or 
exhaustion for monocytes or macrophages has been evidenced to date. It is 
interesting to question whether even in the presence of heavy leukaemic or other 
tumour burdens saturation of the reticulo-endothelial system is possible given its 
huge capacity for cellular uptake and clearance. Indeed under normal homeostatic 
conditions phagocytic cells of the liver and spleen have been calculated to clear 2 
million red blood cells per second [47]. 
 
Shaving, albeit not so-called at the time, was first demonstrated by Griffin and 
colleagues who observed that capped antigen-antibody complexes could be 
internalised by monocytes/macrophages without engulfing or destroying the 
opsonised cells [48]. They had previously shown that antigen-antibody capping 
prevented phagocytic uptake of opsonised cells. They showed in a series of elegant 
studies that the capping process effectively sequestered antibody to one half of the 
target cell which was brought into intimate contact with the effector cell plasma 
membrane. This process left the membrane-distal portion of the target cell denuded 
of opsonising antibody thereby preventing the zipper mechanism of phagocytic 
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uptake they had previously outlined [49]. Although these data provide good evidence 
for the ability of antibodies to mediate such a process it should be noted that these 
early studies were carried out with polyclonal antibodies rather than monoclonals. It 
is likely that the use of polyclonal Ab raised against highly expressed receptors such 
as the B cell receptor and their consequent ability to induce extensive hyper cross-
linking produce an exaggerated effect when compared to mAb such as rituximab 
which recognise more discreet antigens and have been demonstrated to produce 
smaller caps [19] rather than the hemisphere sized caps produced in these early 
studies. Despite this caveat, several laboratories have shown similar findings with a 
variety of other mAb (trastuzumab, cetuximab and T101, [50]; epratuzumab, [51]; 
daclizumab, [52]; CD22/CD20 bispecific, [53] and CD3/Trop-2 bispecific, [54]), 
demonstrating that shaving does indeed occur on target cells.  
The questions that remain regarding shaving are as follows: firstly, whether and to 
what extent this phenomenon impacts mAb efficacy in patients and secondly which 
mechanism of resistance, internalisation or shaving, is dominant in limiting 
responses to rituximab. The first question is important in order to help establish the 
rules by which one can predict and therefore rationally design mAb specific to 
antigens on different cell types whilst avoid shaving and potential escape. Secondly, 
for CD20 therapy it is important to understand which of the two resistance 
mechanisms dominate as each has been proposed to require very different clinical 
strategies to reduce or overcome their impact. 
In the case of internalisation we have proposed the use of non-internalising type II 
CD20 mAb such as obinutuzumab or the concurrent administration of mAb which 
reduce or negate the internalisation process of type I mAb like rituximab (discussed 
below). Alternatively, in order to overcome the detrimental impact of antigen loss 
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through shaving Taylor and colleagues have proposed that repeated low dose 
antibody administration, sufficient to clear cells but not, they suggest to saturate the 
effector populations, will enhance responses in CLL [55] and potentially to other 
direct targeting mAb [45].  
 
Taylor and colleagues in [45] themselves concede that in contrast to their own pilot 
and phase I/II trials [56,57], “the results of a dose escalation trial for CLL indicated a 
higher level of efficacy for single agent rituximab at (higher) weekly doses of 2250 
mg/m2” [58]. Further, the recent randomised Phase II NCRI Attenuated dose 
Rituximab with ChemoTherapy In CLL (ARCTIC) trial of low dose rituximab in 
previously untreated CLL closed the low rituximab arm early as it was inferior to 
standard FCR [59]. It should be noted that although this would suggest that shaving 
is not limiting efficacy in this setting and low dose rituximab regimes are not likely to 
augment responses in CLL these data are confounded by the addition of 
mitoxantrone. 
 
These results do however highlight the larger question regarding the CD20 
low/negative cells observed; are these deletion-resistant circulating cells as Taylor 
and colleagues propose or are they cells in circulation/transit which have shaved and 
escaped initial encounters with effector cells but which will eventually be cleared? 
Taylor and colleagues proposed that shaving was a secondary and separate 
mechanism only evoked when effectors were saturated or exhausted leading to 
resistant circulating cells. However, evidence in support of the latter contention, that 
these are cells in the process of being cleared, comes from a study by Boross et al. 
[41] where they showed that, “RTX-induced trogocytosis of CD20 is dependent on 
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RTX concentration and correlates with the therapeutic effect of CD20, confirming 
that the two processes are intimately related.” Our own unpublished data also 
support the latter statement as we only observe shaving in the presence of 
phagocytic activity in vivo and in vitro. Indeed, if we artificially saturate murine or 
human macrophages in vitro using latex beads we see a saturation-dependent loss 
in shaving which corresponds with a reduction in phagocytosis. Interestingly, and as 
demonstrated by Pedersen et al., both type I and II CD20 mAb mediate shaving 
equally [60] and we have confirmed this in unpublished mouse and human studies. 
Despite this similar propensity to shave, type II mAb outperform type I in mediating 
cellular clearance in vitro and in mouse models in a manner that can instead be 
explained by their lack of propensity to internalise [18,24]. Further to this the type II 
mAb obinituzumab has recently been trialled head to head with rituximab in CLL 
patients in combination with chlorambucil (CLL11, [61]) and found to nearly double 
progression free survival (albeit with a higher dosing schedule for obinituzumab). 
Taken together, these data support that internalisation rather than shaving limits the 
efficacy of type I anti-CD20 mAb. 
 
Other interactions between therapeutic mAb and inhibitory FcγRIIB that limit 
therapeutic efficacy 
In addition to reduced therapeutic efficacy mediated by the loss of opsonised antigen 
from the surface of a target cell via internalisation or shaving, there are additional 
interactions between therapeutic mAb and FcγRIIB that may increase resistance to 
depletion. These effects are mediated via interaction between FcγRIIB and 
therapeutic mAb in cis or trans and are discussed below (Figure 1). 
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Cis effects 
It is clear that mAb targeting specific cell-surface receptors on FcγRIIB–expressing 
cells can, and do, interact with FcγRIIB in cis [20,62]. The consequences of this 
interaction are both target and mAb specific. Firstly, cis interaction between mAb and 
FcγRIIB can compete with other FcγR expressed in trans leading to a potential 
reduction in downstream FcγR-dependent immune effector mechanisms. This was 
demonstrated by Cassard et al. using an in vivo model in which mice were 
challenged with a metastatic melanoma cell line transfected with FcγRIIB. Survival of 
mice challenged with these cells was reduced after treatment with a direct tumour 
targeting therapeutic antibody, compared to mice challenged with the untransfected 
FcγRIIB-ve cells. This effect was independent of the FcγRIIB cytoplasmic domain 
and resulted in lower antibody-dependent cellular cytotoxicity in vitro [62]. We would 
predict that cis interactions between FcγRIIB and therapeutic mAb would also likely 
compete with activatory FcγR expressed in trans on professional phagocytic cells, 
reducing antibody-dependent phagocytosis of cellular targets and thereby clinical 
efficacy. Further, if the opsonised target acts as an adjuvant to boost the immune 
response via engagement of activatory FcγR, reduced uptake of opsonised cells by 
professional antigen presenting cells could also result in reduced antigen-specific 
responses directed against tumour specific antigens. 
Interactions between therapeutic mAb and FcγRIIB expressed in cis may also 
compete with complement proteins for binding to the Fc domain of antibodies. Type I 
anti-CD20 mAb efficiently fix complement, activating the classical complement 
cascade [12]. Although this activity is largely considered dispensable for the 
therapeutic effects of the antibodies in vivo [23], Wang et al. have demonstrated that 
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complement components C1q and C3 inhibit the ability of type I anti-CD20 mAb to 
activate NK cells via FcγRIII expressed in trans, resulting in reduced ADCC [63]. 
This effect is presumably due to competition between complement and FcγR for 
binding to the Fc domain of the therapeutic mAb. Although not shown 
experimentally, a similar effect might occur between complement and FcγRIIB 
expressed in cis, in which the two proteins may compete for binding to the Fc of the 
therapeutic mAb. Therefore, with mAb for which complement activation is 
therapeutically important, cis interactions with FcγRIIB may be detrimental. 
 
Trans effects 
We have demonstrated that mAb targeting B cell surface receptor proteins are 
capable of binding to FcγRIIB expressed in cis and trans [20]. Trans interaction with 
FcγRIIB expressed on professional phagocytic cells lowers the therapeutic efficacy 
of direct targeting mAb [64,65], presumably due to competition for Fc binding sites 
with activatory FcγR on the phagocytes and inhibition of cellular activation via the 
downstream inhibitory effects of FcγRIIB engagement. The ratio of activatory FcγR 
to inhibitory FcγRIIB engaged by a therapeutic mAb is termed the 
activatory:inhibitory ratio [65,66], and is determined by cellular FcγR expression and 
the mAb IgG subtype. In mice, mouse IgG1 has a higher affinity for the inhibitory 
FcγR than mouse IgG2a [66], and thus has a lower activatory:inhibitory ratio and 
reduced therapeutic efficacy [24]. The deleterious effect of trans engagement 
between therapeutic mAb and FcγRIIB and the importance of activatory:inhibitory 
ratio was demonstrated by Nimmerjahn et al. using mice challenged with a 
metastatic melanoma cell line. Treatment of mice with the IgG2a subtype of a direct 
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tumour targeting mAb, which has an activatory:inhibitory ratio of 70 dramatically 
reduced the number of lung metastases to almost zero, compared to untreated mice. 
Conversely, treatment of mice with the IgG1 subtype resulted in no reduction in lung 
metastases due to the lower activatory:inhibitory ratio (0.1). However, in mice in 
which the gene encoding FcγRIIB had been deleted so that mAb could only engage 
activatory FcγR, the therapeutic efficacy of the IgG1 subtype was substantially 
augmented [65]. Thus, the degree of trans engagement between direct targeting 
mAb and FcγRIIB may have a direct effect on the outcome of therapy. This may be 
relevant in the treatment of various human malignancies, including malignant 
melanoma in which FcγRIIB expression is expressed on up to 40% of metastatic 
tumours [67]. Such ectopic expression of FcγRIIB on the tumour cells themselves (or 
on non-haematopoietic cells associated with it) could compete for mAb binding with 
activatory FcγR expressed on effector cells at the tumour site, lowering the 
activatory:inhibitory ratio of therapeutic mAb and reducing clinical efficacy. 
 
Future strategies to reverse mAb resistance mechanisms 
Co-administration of FcγRIIB blocking mAb and anti-CD20 mAb for the treatment of 
B cell malignancies 
Concentrating on anti-CD20 mAb, we have highlighted the diverse range of 
mechanisms through which therapeutic mAb can interact with FcγRIIB to result in 
reduced efficacy. Remarkably, the majority of these inhibitory mechanisms can 
potentially be abrogated using a single strategy; blocking FcγRIIB. Roghanian et al. 
recently co-treated mice expressing human CD20 and FcγRIIB with both rituximab 
and an FcγRIIB-specific blocking mAb, 6G11[68]. As expected, treatment of cells 
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with the FcγRIIB-blocking mAb reduced the rate of internalisation of mAb-ligated 
CD20 from the surface of B cells in vitro and this corresponded with an enhanced 
depletion of B cells in vivo. Furthermore, we observed a similar augmentation of B 
cell depletion when rituximab was combined with an N297Q mutant form of 6G11 
unable to bind FcγR by its Fc domain [68]. This suggested that the enhanced 
therapy seen was, at least in part, due to the inhibition of rituximab-mediated 
internalisation by preventing bipolar antibody bridging with FcγRIIB.  
 
In addition to inhibiting internalisation, blocking bipolar antibody bridging should 
promote interaction between direct targeting mAb and FcγR expressed in trans. Use 
of an FcγRIIB-blocking mAb such as 6G11 would also be expected to prevent trans 
interactions between direct targeting mAb and FcγRIIB on phagocytic cells and 
tumour cells, thereby enhancing the activatory:inhibitory ratio of the antibody, further 
enhancing therapeutic efficacy. 
 
With such a variety of effector mechanisms potentially augmented by co-
administration of 6G11, it will be exciting to see how this mAb performs in up-coming 
clinical trials [69]. If successful, co-treatment with blocking anti-FcγRIIB mAb may be 
applicable to many other direct targeting antibody therapeutics, and possibly some 
agonistic mAb. For example, for mAb which have been chosen for their ability to 
activate cell-surface receptors, blocking the interaction with FcγRIIB may augment 
activation due to the tendency of the inhibitory receptor to otherwise terminate 
downstream signalling pathways [70]. Paradoxically however, cross-linking by 
FcγRIIB expressed in trans has been demonstrated to be essential for the agonistic 
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activity of certain mAb such as anti-CD40 [71,72]. Therefore, blocking FcγRIIB in this 
context may actually be detrimental and so the use of this approach would need to 
be evaluated for each agonistic antibody depending on its mechanism of action. 
 
Conclusions 
In summary, it is clear that mAb have begun to revolutionise medical intervention, 
particularly in oncology, and this trend is set to continue [73]. Since the approval of 
rituximab in 1997, a plethora of other mAb have followed and become embedded 
into clinical practice. A completely different therapeutic modality to conventional 
chemotherapy, it is unsurprising that its resistance mechanisms also vary. Here we 
have outlined the way in which internalisation, shaving and other FcγRIIB-mediated 
mechanisms can reduce mAb efficacy, particularly for anti-CD20 mAb. If in the 
coming years effective strategies to overcome each of these issues are realised, 
even more impressive clinical responses with mAb therapeutics will be provided. 
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Figure legends 
Figure 1. Potential means of mAb resistance. Two key modes of mAb resistance 
have been proposed; internalisation/modulation or “shaving”.  In the former, a cell 
intrinsic process occurs whereby mAb binds to the target antigen (e.g. CD20) and its 
Fc is engaged by the inhibitory FcRIIB, precipitating internalisation of the tripartite 
complex. In contrast, shaving is performed by a secondary phagocytic cell. Under 
certain conditions, such as target cell saturation, the activatory FcR rather than 
mediating phagocytosis of the target cell, rip a portion of the cell membrane 
containing the target antigen and antibody from the target cell, stripping it of mAb 
and antigen. 
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